Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3002787 | 0.91 | MEN1 (0.37) | MEN1KMT2APDE3BPDE3AP2RY12 | |
| SCHEMBL3554796 | 0.90 | FFAR4 (0.41) | MEN1KMT2APDE3BPDE3AP2RY12 | |
| SCHEMBL2999221 | 0.87 | MMP2 (0.41) | MAPTHRH3ALDH1A1HSD17B10 | |
| SCHEMBL3548272 | 0.84 | KMT2A (0.37) | MEN1KMT2A | |
| SCHEMBL4697044 | 0.83 | PDE3B (0.43) | MEN1KMT2APDE3BPDE3AP2RY12 | |
| SCHEMBL208481 | 0.82 | SLC6A3 (0.41) | MEN1KMT2AMAPTSLC6A3ALDH1A1 | |
| SCHEMBL3548869 | 0.81 | FFAR4 (0.42) | MEN1KMT2APDE3BPDE3AP2RY12 | |
| SCHEMBL3004306 | 0.79 | PPARA (0.39) | MEN1KMT2AMAPTSLC6A3ALDH1A1 | |
| Methane SCHEMBL2993577 | 0.79 | KDM4E (0.35) | MEN1KMT2APDE3BPDE3AP2RY12 | |
| SCHEMBL3001203 | 0.79 | FFAR4 (0.43) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184764-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2010-07-22 | — | — | US | disclosed |
| US-7713979-B2 | Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2010-05-11 | — | — | US | disclosed |
| EP-1807072-B1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2009-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184764-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD17B1, HSD3B1 | MEN1 2203/4885KMT2A 2654/4885PDE3B 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.